Intech Investment Management LLC Invests $79,000 in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Intech Investment Management LLC acquired a new stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 14,628 shares of the biotechnology company’s stock, valued at approximately $79,000.

A number of other hedge funds have also made changes to their positions in ALDX. King Wealth Management Group grew its holdings in shares of Aldeyra Therapeutics by 24.5% in the 3rd quarter. King Wealth Management Group now owns 13,700 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 2,700 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in Aldeyra Therapeutics by 14.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,734 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 2,729 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Aldeyra Therapeutics by 7.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 48,273 shares of the biotechnology company’s stock worth $158,000 after buying an additional 3,446 shares during the period. Providence Wealth Advisors LLC lifted its stake in Aldeyra Therapeutics by 16.3% during the second quarter. Providence Wealth Advisors LLC now owns 25,000 shares of the biotechnology company’s stock valued at $84,000 after buying an additional 3,500 shares in the last quarter. Finally, Laidlaw Wealth Management LLC boosted its holdings in shares of Aldeyra Therapeutics by 32.6% in the second quarter. Laidlaw Wealth Management LLC now owns 16,875 shares of the biotechnology company’s stock worth $56,000 after buying an additional 4,150 shares during the period. Institutional investors and hedge funds own 59.71% of the company’s stock.

Aldeyra Therapeutics Stock Up 5.5 %

Aldeyra Therapeutics stock opened at $5.22 on Monday. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80. Aldeyra Therapeutics, Inc has a fifty-two week low of $2.71 and a fifty-two week high of $6.55. The firm’s 50 day simple moving average is $5.17 and its 200-day simple moving average is $4.69.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, hitting the consensus estimate of ($0.25). Analysts anticipate that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current fiscal year.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.